Global Cardiovascular and Soft Tissue Repair Patches Market, by Type (EPTFE, Biomaterial, Tissue Engineered Material), By Application (Cardiac Repair, Vascular Repair, Pericardial Repair, Dural Repair, Soft Tissue Repair) – Industry Trends and Forecast to 2029
Market Analysis and Size
According to an NCBI article published in December 2019 on trends and prevalence of atrial septal defect, ASD is the second most common kind of congenital heart disease, with an incidence rate of 56 per 100,000 live births worldwide and a prevalence of 1.6 per 1,000 live births. As people become more conscious for the need of early diagnosis and identification of congenital cardiac diseases, leading companies are focused on innovation and the development of technologically advanced products. These technological developments have far-reaching ramifications for product development, raw material manufacturing, and clinical applications. Vascular repair and reconstruction, soft tissue repairs, and dural repairs are all examples of tissue repair patches utilized in surgical operations.
Data Bridge Market Research analyses that the cardiovascular and soft tissue repair patches market which was USD 3.8 billion in 2021, would rocket up to USD 7.09 billion by 2029, and is expected to undergo a CAGR of 8.10% during the forecast period 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Patches for vascular and soft tissue healing are used in vascular repair, soft tissue repair, and restoration operations. The rising occurrence of heart defects such ventricular septal and atrial septal defects in medical events and sports wounds is driving demand for cardiovascular and soft tissue repair patches. The increased prevalence of hernias such inguinal hernias, congenital diaphragmatic hernias, and others is expected to drive global adoption of these patches.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (EPTFE, Biomaterial, Tissue Engineered Material), By Application (Cardiac Repair, Vascular Repair, Pericardial Repair, Dural Repair, Soft Tissue Repair)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
CryoLife, Inc. (U.S), Edwards Lifesciences Corporation (U.S), Bard Peripheral Vascular (U.S), Baxter (U.S), Anteris (U.S), Neovasc Inc. (Canada), Southernlight Biomaterials ( New Zealand), Medtronic ( Ireland), GETINGE AB (Sweden), W. L. Gore & Associates, Inc. (U.S), Abbott (U.S), LeMaitre Vascular Inc. (U.S), BioIntegral Surgical (Canada)., Laboratory Corporation of America Holdings (U.S), Terumo Medical Corporation (U.S), Perouse Medical (France), Gunze Limited (U.S), Maverick Biosciences (U.S)
|
|
Market Opportunities
|
|
Cardiovascular and Soft Tissue Repair Patches Market Dynamics
Drivers
This growth is attributed to rising prevalence of congenital heart disorders such as atrial septal defect and ventricular septal defect and increasing technological advancements and research and development (R&D) expenditure. The rising occurrence of congenital cardiac illnesses such as atrial septal defect and ventricular septal defect, as well as technical improvements, are the primary driving forces in this market.
The increased need for patches in the diagnosis and treatment of cardiac and soft tissue disorders is pushing collaboration efforts among numerous research institutes, raw material suppliers, and key manufacturers to develop breakthrough solutions. Furthermore, main players are focusing on developing novel tissue engineering materials-based technologies, which are expected to drive the progress of the market for cardiovascular and soft tissue repair patches..
- ePTFE Segment to Benefit from Demand for Manufacturing Medical Devices
ePTFE accounted for the highest share of the global cardiovascular and soft tissue repair patch market in terms of raw material, growing at a CAGR of 10.2 percent over the forecast period. By raw material, ePTFE accounted for 62.8 percent of the global cardiovascular and soft tissue repair patch market in 2019. Medical accessories such as transducer protectors, wound-care materials, face masks, ostomy bags, urine bags, drainage bags, and medical device enclosures all use ePTFE.
- Treatment for Hernias
The soft tissue repair segment is expected to increase at a CAGR of 9.7% during the forecast period. The sector accounted for 35.1 percent of the global cardiovascular and soft tissue repair patch market, the biggest proportion. The rise in prevalence of various forms of hernias, such as umbilical hernias, inguinal hernias, ventral hernias, and others, is responsible for the increase.
- Increasing prevalence of heart conditions
The presence of sophisticated health-care infrastructure, significant players, and a large number of research activities are the primary drivers driving market expansion in the region. Furthermore, the rising prevalence of cardiac diseases as a result of sedentary lifestyles, junk food intake, alcohol, cigarettes, and substance misuse are some of the important variables that support favourable regional growth.
Opportunities
- Rapidly expanding prevalence of congenital cardiac illnesses
In addition, the increasing use of patches in medical procedures and the rise in sports injuries are likely to help the market's development and growth in the next years. According to research, ASD is the second most frequent type of congenital heart disease, with an incidence rate of 56 per 100,000 live births worldwide.
- Improvements in Bio-based Techniques to Treat Cardiac Regeneration
Cardiovascular illnesses are the largest cause of death worldwide, and the number of people dying from them is increasing every year. Myocardial infarction (MI) has the greatest frequency of all major cardiovascular disorders. Heart failure, in which the heart loses its functional capacities, is another important cardiovascular ailment that is anticipated to be a burden on global healthcare systems. While there is no specific treatment for heart failure, research and development initiatives in this field continue to offer new doors.
Restraints/Challenges
The market's growth is hampered by customers' lack of awareness about the patches and the high costs of treatments. Mesh for hernia repair and valves for cardiovascular repair are widely used worldwide. Alternative treatments are thus expected to stifle the market for cardiovascular and soft tissue restoration. Patch problems include adhesion, seroma, recurrence of soft tissue defects or hernias, allergic reactions, and hematomas, all of which limit their use.
This cardiovascular and soft tissue repair patches market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cardiovascular and soft tissue repair patches market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Cardiovascular and Soft Tissue Repair Patches Market
As the COVID-19 issue worsens, a series of positive and negative shocks will emerge over the next few months as producers and vendors adjust to changing client needs. To satisfy the need of a pandemic that has lowered the requirement for Cardiovascular and Soft Tissue Repair Patch, manufacturers are fast adjusting their methods and purchasing objectives.
Recent Development
Terumo will launch AQUABRID, a new surgical sealant, in the EMEA market in February 2020. AQUABRID is authorised for use as an adjuvant to established methods of cardiovascular surgical repair to seal (such as staples, sutures, patches, and electrocautery) linked to aorta surgery.
CorMatrix unveiled the first minimally invasive robotic implant of Cor PATCH in January 2020.
Global Cardiovascular and Soft Tissue Repair Patches Market Scope
The cardiovascular and soft tissue repair patches market is segmented on the basis of type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- EPTFE
- Biomaterial
- Tissue Engineered Material
Application
- Cardiac repair
- Atrial septal defect
- Common atrium
- Defects of the endocardial cushion
- Ventricular septal defect
- Tetralogy of Fallot
- Right ventricular outflow tract reconstruction
- Suture bleeding
- Vascular repair and reconstruction
- Carotid endarterectomy
- Anomalous connection of the pulmonary veins
- Transposition of the great vessels
- Reconstruction of portal and superior mesenteric veins
Other Vascular repair and reconstruction
- Pericardial repair
- Dural repair
- Soft Tissue repair
- Defects of the abdominal wall
- Defects of the thoracic wall
- Gastric binding
- Hernias
The cardiovascular and soft tissue repair patches market is analysed and market size insights and trends are provided by country, type and application as referenced above.
The countries covered in the cardiovascular and soft tissue repair patches market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominated the market for cardiovascular and soft tissue repair patches, accounting for 37.6 percent of sales in 2021. This is due to quickly changing lifestyles, an increase in the incidence of cardiac diseases, an increase in the number of hernia problems, an increase in alcohol consumption and smoking, an increase in obesity, and an increase in substance addiction.
Due to rapid developments in healthcare infrastructure, growing trends of minimally invasive surgical procedures, rising incidence of cardiac disease, increasing medical tourism, rapid economic expansion in several countries such as China and India, rising geriatric population, and increasing burden of chronic disorders, Asia Pacific is expected to register the fastest growing rate in the coming years. Raising awareness about the importance of early diagnosis and detection of congenital cardiac disorders, as well as quick treatment.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The cardiovascular and soft tissue repair patches market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for cardiovascular and soft tissue repair patches market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the cardiovascular and soft tissue repair patches market. The data is available for historic period 2010-2020.
Competitive Landscape and Cardiovascular and Soft Tissue Repair Patches Market Share Analysis
The cardiovascular and soft tissue repair patches market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cardiovascular and soft tissue repair patches market.
Some of the major players operating in the cardiovascular and soft tissue repair patches market are:
- CryoLife, Inc. (U.S)
- Edwards Lifesciences Corporation (U.S)
- Bard Peripheral Vascular (U.S)
- Baxter (U.S)
- Anteris (U.S)
- Neovasc Inc. (Canada)
- Southernlight Biomaterials ( New Zealand)
- Medtronic ( Ireland)
- GETINGE AB (Sweden)
- W. L. Gore & Associates, Inc. (U.S)
- Abbott (U.S)
- LeMaitre Vascular Inc. (U.S)
- BioIntegral Surgical (Canada)
- Laboratory Corporation of America Holdings (U.S)
- Terumo Medical Corporation (U.S)
- Perouse Medical (France)
- Gunze Limited (U.S)
- Maverick Biosciences (U.S)
SKU-